Telavancin Hydrochloride

CHEMBL3301680 Phase 4 Onaylandı Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1792.1 g/mol

LogP

—

Phase

4

Telavancin hydrochloride is the hydrochloride salt form of telavancin, a lipoglycopeptide antibiotic with dual cell wall and membrane-disrupting mechanisms active against gram-positive bacteria including MRSA. See telavancin for complete pharmacological details. This salt formulation is used in the intravenous preparation for treatment of serious gram-positive infections including hospital-acquired pneumonia and chronic kidney disease-related infections.

Moleküler Ağırlık

1792,1000 g/mol

TPSA

598,00 Å²

Terapötik Alanlar

Chronic Kidney Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O.Cl

InChI

InChI=1S/C80H106Cl2N11O27P.ClH/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39;/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114);1H/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-;/m0./s1

Molecular Formula

C80H107Cl3N11O27P

HBD / HBA

24 / 31

Döndürülebilir Bağlar

30

Ağır Atomlar

122

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Telavancin hydrochloride is the hydrochloride salt form of telavancin, a lipoglycopeptide antibiotic with dual cell wall and membrane-disrupting mechanisms active against gram-positive bacteria including MRSA. See telavancin for complete pharmacological details. This salt formulation is used in the intravenous preparation for treatment of serious gram-positive infections including hospital-acquired pneumonia and chronic kidney disease-related infections.

Yes, Telavancin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301680. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9812715. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Telavancin Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C80H107Cl3N11O27P
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.